Back

This OncLive Insights features 3 experts who elucidate treatment advances for patients with Chronic Lymphocytic Leukemia (CLL). Considering both the frontline and relapsed/refractory setting, these key opinion leaders share their perspectives on optimal risk stratification, molecular targets, and sequencing strategies given data from recent clinical trials.

Therapeutic Advances for Patients With Chronic Lymphocytic Leukemia

Episodes

Specialty:

All

Year:

All

EP. 1: Impact of Targeted Therapy in CLL

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

July 30th 2021

Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.

EP. 2: Frontline Therapy for Patients With CLL: Testing and Risk Classification

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

July 30th 2021

A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.

EP. 3: Global Approaches to the Frontline Management of CLL

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

August 9th 2021

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

EP. 4: Key Clinical Data for Frontline Targeted Therapy in CLL

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

August 9th 2021

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.

EP. 5: Optimizing the Frontline Management of High-Risk CLL

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

August 16th 2021

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

EP. 6: Frontline Targeted Therapy in CLL: Tolerability and Toxicity Management

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

August 16th 2021

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

EP. 7: Which Path to Take in Frontline Therapy for CLL?

ByJohn C. Byrd, MD, Ohio State University,Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele,Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

August 23rd 2021

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.